The Pharma Data

NOVEMBER 8, 2020

Almirall strengthens its leadership in medical dermatology by reinforcing its management team in France and obtaining reimbursement in France of Ilumetri ® (tildrakizumab) for treating moderate to severe chronic plaque psoriasis in adults. Investment in Research & Development remained at c. .

Dermatology 52

Dermatology Sales Marketing Production 52

The Pharma Data

AUGUST 17, 2021

Effective September 5, Lilly Bio-Medicines will split into two business units: Lilly Neuroscience and Lilly Immunology. The company recently announced Breakthrough Therapy designation for donanemab and its intention to submit a biologics license application (BLA) under the accelerated approval pathway later this year.

Medicine 52

Medicine Dermatology Production Development 52

The Pharma Data

JANUARY 12, 2021

Dr Graham is a medicines development expert and Infectious Diseases Epidemiologist with global Biotech and Pharma R&D experience in Phase I-IV therapeutics as well as in-vivo & in-vitro diagnostics, across many modalities. He has in depth Global Development Expertise (e.g.

Life Science 52

Life Science Antibody In-Vivo In-Vitro 52

XTalks

AUGUST 2, 2023

They are committed to capitalizing on growth opportunities primarily through the advancement of their own product pipeline and constantly improving their existing products, as well as through business development activities. billion the drug generated in 2021. Pfizer’s total global revenue in 2022 from Comirnaty was $37.81

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

MAY 18, 2021

This business developed positively in the Europe/Middle East/Africa region and in Latin America, partly as a result of higher prices, whereas it shrank in North America, in part due to a license expiration. In the United States, the division benefited particularly from the launch of the cancer drug Nubeqa™. percent and 4.7

Sales 40

Sales Production Marketing Containment 40

The Pharma Data

AUGUST 3, 2021

We expect that recovery in the dermatology segment will continue to progress over the coming quarters. Research & Development (R&D) expenses increased 12% primarily due to higher research and early pipeline spend and late-stage development program spend, including our recent business development activities.

Sales 52

Sales Production Antibody Development 52

Pharma Marketing Network

OCTOBER 27, 2020

So a doctor that’s licensed stay only in the state of New York would be able to practice across the entire counties using Telemedicine. Don ( PMN): Sure. And so you’re involved in these companies, how does that play into your overall role as a thought leader in the healthcare space?

Insulin 52

Insulin Marketing Doctors Doctor 52